BIPHETAMINE 7.5
LOE ApproachingNDAORALCAPSULE, EXTENDED RELEASE
Approved
Sep 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BIPHETAMINE 7.5 is an extended-release oral capsule approved in 1955 by UCB Pharma as an NDA product. The specific indication and mechanism of action are not documented in available data, limiting clinical context. This legacy product represents a significant portion of UCB's historical portfolio.
LOE Approaching
With LOE approaching and zero linked job postings, this product is in portfolio wind-down mode with minimal team expansion opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
BIPHETAMINE 7.5 offers minimal career growth opportunity due to its LOE status and absence of any linked job postings. Roles on this product focus on portfolio stewardship and revenue protection rather than expansion or innovation.
Brand Manager (legacy portfolio)Field Sales (account maintenance)
Worked on BIPHETAMINE 7.5 at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.